Bristol Myers prunes pipeline amid new round of cost cuts
Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials. The pipeline cuts disclosed Thursday follow news of a

Apr 15, 2025 0
Apr 15, 2025 0
Apr 9, 2025 0
Apr 9, 2025 0
Apr 9, 2025 0
Apr 9, 2025 0
Apr 15, 2025 0
Or register with email
Feb 13, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 19, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.